This morning, The New York Times published a devastating exposé on the traditional PBM industry. The article shines a blazing spotlight on the traditional PBM practices that prioritize rebate-driven drug volume to maximize profits. Practices like these are hurting plan sponsors, members/patients, community pharmacies, and many other stakeholders. Clearly illustrating why a clinically-driven, customer-first pharmacy care alternative is more vital than ever, below is how the NY Times described the self-dealing practices of the Big 3 PBMs: “The job of the P.B.M.s is to reduce drug costs. Instead, they frequently do the opposite. They steer patients toward pricier drugs, charge steep markups on what would otherwise be inexpensive medicines and extract billions of dollars in hidden fees, a New York Times investigation found.” Read the full article here. https://lnkd.in/eU6p-vFb EmpiRx Health's clinically-driven pharmacy care approach is by far the best alternative to the legacy PBMs, who prioritize their own profits at the expense of their customers. Want to learn more about why plan sponsors and their advisors and consultants are increasingly choosing EmpiRx Health for their pharmacy benefits care? Contact us today! https://lnkd.in/eeiGZpxM #PBM #Healthcare #NewYorkTimes
Clinically™ - Powered by EmpiRx Health’s Post
More Relevant Posts
-
EmpiRx Health was founded 10 years ago to deliver not just PBM services but to provide clinical outcomes and reduce healthcare cost for members and client. Doing the same thing over and over has not worked - highlighted by the article below. Let’s talk about outcomes, service, and total spend for an end-to-end solution! #pbm #clinical #populationhealth #service #culture #healthcare #newyorktimes #Clinically
This morning, The New York Times published a devastating exposé on the traditional PBM industry. The article shines a blazing spotlight on the traditional PBM practices that prioritize rebate-driven drug volume to maximize profits. Practices like these are hurting plan sponsors, members/patients, community pharmacies, and many other stakeholders. Clearly illustrating why a clinically-driven, customer-first pharmacy care alternative is more vital than ever, below is how the NY Times described the self-dealing practices of the Big 3 PBMs: “The job of the P.B.M.s is to reduce drug costs. Instead, they frequently do the opposite. They steer patients toward pricier drugs, charge steep markups on what would otherwise be inexpensive medicines and extract billions of dollars in hidden fees, a New York Times investigation found.” Read the full article here. https://lnkd.in/eU6p-vFb EmpiRx Health's clinically-driven pharmacy care approach is by far the best alternative to the legacy PBMs, who prioritize their own profits at the expense of their customers. Want to learn more about why plan sponsors and their advisors and consultants are increasingly choosing EmpiRx Health for their pharmacy benefits care? Contact us today! https://lnkd.in/eeiGZpxM #PBM #Healthcare #NewYorkTimes
To view or add a comment, sign in
-
-
Today's NY Times article really told the tale of how the big 3 legacy PBMs have so negatively impacted the healthcare system writ large. Please read the Times article and let us know what you think.
This morning, The New York Times published a devastating exposé on the traditional PBM industry. The article shines a blazing spotlight on the traditional PBM practices that prioritize rebate-driven drug volume to maximize profits. Practices like these are hurting plan sponsors, members/patients, community pharmacies, and many other stakeholders. Clearly illustrating why a clinically-driven, customer-first pharmacy care alternative is more vital than ever, below is how the NY Times described the self-dealing practices of the Big 3 PBMs: “The job of the P.B.M.s is to reduce drug costs. Instead, they frequently do the opposite. They steer patients toward pricier drugs, charge steep markups on what would otherwise be inexpensive medicines and extract billions of dollars in hidden fees, a New York Times investigation found.” Read the full article here. https://lnkd.in/eU6p-vFb EmpiRx Health's clinically-driven pharmacy care approach is by far the best alternative to the legacy PBMs, who prioritize their own profits at the expense of their customers. Want to learn more about why plan sponsors and their advisors and consultants are increasingly choosing EmpiRx Health for their pharmacy benefits care? Contact us today! https://lnkd.in/eeiGZpxM #PBM #Healthcare #NewYorkTimes
To view or add a comment, sign in
-
-
This NY Times article really captures the breadth and depth of the incredibly negative impact of the Big 3 PBM players on the healthcare system, especially the plan sponsors and their members. There is a better way, and it is the clinically-driven pharmacy care provided by EmpiRx Health. Check it out!
This morning, The New York Times published a devastating exposé on the traditional PBM industry. The article shines a blazing spotlight on the traditional PBM practices that prioritize rebate-driven drug volume to maximize profits. Practices like these are hurting plan sponsors, members/patients, community pharmacies, and many other stakeholders. Clearly illustrating why a clinically-driven, customer-first pharmacy care alternative is more vital than ever, below is how the NY Times described the self-dealing practices of the Big 3 PBMs: “The job of the P.B.M.s is to reduce drug costs. Instead, they frequently do the opposite. They steer patients toward pricier drugs, charge steep markups on what would otherwise be inexpensive medicines and extract billions of dollars in hidden fees, a New York Times investigation found.” Read the full article here. https://lnkd.in/eU6p-vFb EmpiRx Health’s clinically-driven pharmacy care approach is by far the best alternative to the legacy PBMs, who prioritize their own profits at the expense of their customers. Want to learn more about why plan sponsors and their advisors and consultants are increasingly choosing EmpiRx Health for their pharmacy benefits care? Contact us today! https://lnkd.in/eeiGZpxM #PBM #Healthcare #NewYorkTimes
To view or add a comment, sign in
-
-
This morning, The New York Times published a devastating exposé on the traditional PBM industry. The article shines a blazing spotlight on the traditional PBM practices that prioritize rebate-driven drug volume to maximize profits. Practices like these are hurting plan sponsors, members/patients, community pharmacies, and many other stakeholders. Clearly illustrating why a clinically-driven, customer-first pharmacy care alternative is more vital than ever, below is how the NY Times described the self-dealing practices of the Big 3 PBMs: “The job of the P.B.M.s is to reduce drug costs. Instead, they frequently do the opposite. They steer patients toward pricier drugs, charge steep markups on what would otherwise be inexpensive medicines and extract billions of dollars in hidden fees, a New York Times investigation found.” Read the full article here. https://lnkd.in/eU6p-vFb EmpiRx Health’s clinically-driven pharmacy care approach is by far the best alternative to the legacy PBMs, who prioritize their own profits at the expense of their customers. Want to learn more about why plan sponsors and their advisors and consultants are increasingly choosing EmpiRx Health for their pharmacy benefits care? Contact us today! https://lnkd.in/eeiGZpxM #PBM #Healthcare #NewYorkTimes
To view or add a comment, sign in
-
-
Employers and business owners who are tired of the traditional PBM experience need to read this article.
This morning, The New York Times published a devastating exposé on the traditional PBM industry. The article shines a blazing spotlight on the traditional PBM practices that prioritize rebate-driven drug volume to maximize profits. Practices like these are hurting plan sponsors, members/patients, community pharmacies, and many other stakeholders. Clearly illustrating why a clinically-driven, customer-first pharmacy care alternative is more vital than ever, below is how the NY Times described the self-dealing practices of the Big 3 PBMs: “The job of the P.B.M.s is to reduce drug costs. Instead, they frequently do the opposite. They steer patients toward pricier drugs, charge steep markups on what would otherwise be inexpensive medicines and extract billions of dollars in hidden fees, a New York Times investigation found.” Read the full article here. https://lnkd.in/eU6p-vFb EmpiRx Health’s clinically-driven pharmacy care approach is by far the best alternative to the legacy PBMs, who prioritize their own profits at the expense of their customers. Want to learn more about why plan sponsors and their advisors and consultants are increasingly choosing EmpiRx Health for their pharmacy benefits care? Contact us today! https://lnkd.in/eeiGZpxM #PBM #Healthcare #NewYorkTimes
To view or add a comment, sign in
-
-
So many want PBM reform but they keep using the big five! Consider the simple rule of "doing the right thing." In today's landscape, we can identify three types of Pharmacy Benefit Managers (PBMs): 1. The "big 5" PBMs prioritize driving up drug spend above all else. It's as simple as that. 2. There are a few mid-market PBMs that focus on transparency but struggle with profitability. They will not stand the test of time, operating as one-hit wonders. 3. Enter EmpiRx - our model doesn't revolve around volume; it's all about clinical excellence! Picture a dedicated team working behind the scenes, ensuring you receive the best therapy consistently. No steering towards preferred drugs, just a 100% open formulary approach. By doing what's right, everything else falls into place. Embrace the change that prioritizes better health outcomes and savings. Be bold and make a difference!
This morning, The New York Times published a devastating exposé on the traditional PBM industry. The article shines a blazing spotlight on the traditional PBM practices that prioritize rebate-driven drug volume to maximize profits. Practices like these are hurting plan sponsors, members/patients, community pharmacies, and many other stakeholders. Clearly illustrating why a clinically-driven, customer-first pharmacy care alternative is more vital than ever, below is how the NY Times described the self-dealing practices of the Big 3 PBMs: “The job of the P.B.M.s is to reduce drug costs. Instead, they frequently do the opposite. They steer patients toward pricier drugs, charge steep markups on what would otherwise be inexpensive medicines and extract billions of dollars in hidden fees, a New York Times investigation found.” Read the full article here. https://lnkd.in/eU6p-vFb EmpiRx Health’s clinically-driven pharmacy care approach is by far the best alternative to the legacy PBMs, who prioritize their own profits at the expense of their customers. Want to learn more about why plan sponsors and their advisors and consultants are increasingly choosing EmpiRx Health for their pharmacy benefits care? Contact us today! https://lnkd.in/eeiGZpxM #PBM #Healthcare #NewYorkTimes
To view or add a comment, sign in
-
-
Improved long-term health outcomes is our focus. Patient health & well-being always come first with EmpiRx.
This morning, The New York Times published a devastating exposé on the traditional PBM industry. The article shines a blazing spotlight on the traditional PBM practices that prioritize rebate-driven drug volume to maximize profits. Practices like these are hurting plan sponsors, members/patients, community pharmacies, and many other stakeholders. Clearly illustrating why a clinically-driven, customer-first pharmacy care alternative is more vital than ever, below is how the NY Times described the self-dealing practices of the Big 3 PBMs: “The job of the P.B.M.s is to reduce drug costs. Instead, they frequently do the opposite. They steer patients toward pricier drugs, charge steep markups on what would otherwise be inexpensive medicines and extract billions of dollars in hidden fees, a New York Times investigation found.” Read the full article here. https://lnkd.in/eU6p-vFb EmpiRx Health’s clinically-driven pharmacy care approach is by far the best alternative to the legacy PBMs, who prioritize their own profits at the expense of their customers. Want to learn more about why plan sponsors and their advisors and consultants are increasingly choosing EmpiRx Health for their pharmacy benefits care? Contact us today! https://lnkd.in/eeiGZpxM #PBM #Healthcare #NewYorkTimes
To view or add a comment, sign in
-
-
Reducing the cost of drugs is important, to be sure, but the most expensive drug is the one that doesn't work. At DecisionRx, Inc., we make sure individuals take the right drugs for them, eliminating the 16% of wasted health care costs directly caused by medication failure. When we know better, we must do better—now is the time. #medicationmanagement #precisionmedicine #valuebasedcare
Pharmacy benefit managers were once the solution to the high cost of drugs. Today, they are a contributing factor to that issue. The Los Angeles Times highlights a system that has driven up healthcare costs, making necessary medications less accessible. At DecisionRx, we are committed to lowering healthcare costs through our Medication Therapy Optimization platform. We want to get your medication therapy right from the start through our DNA testing and avoid the unnecessary costs of trial and error prescribing. Learn more here: https://lnkd.in/esMxNPRE #HealthcareCosts #MedicationTherapyOptimization
To view or add a comment, sign in
-
Pharmacy benefit managers were once the solution to the high cost of drugs. Today, they are a contributing factor to that issue. The Los Angeles Times highlights a system that has driven up healthcare costs, making necessary medications less accessible. At DecisionRx, we are committed to lowering healthcare costs through our Medication Therapy Optimization platform. We want to get your medication therapy right from the start through our DNA testing and avoid the unnecessary costs of trial and error prescribing. Learn more here: https://lnkd.in/esMxNPRE #HealthcareCosts #MedicationTherapyOptimization
Column: Pharmacy middlemen claim to keep prescription prices low. In fact, they've cost consumers billions
latimes.com
To view or add a comment, sign in
-
TODAY: Don't miss ATI Advisory CEO Anne Tumlinson and Morgan Health CEO Dan Mendelson (12/12/23) at 2 p.m. ET for a dynamic discussion about the year ahead. What will be some of the challenges and opportunities for healthcare providers, payers, and patients in 2024? You can expect to hear Anne and Dan discuss value-based care, enhanced primary care, retail health, technology, and prescription drug pricing. Register Today: https://lnkd.in/ePS6GkJH #HealthPolicy #Medicare #ValueBasedCare #DrugPricing
To view or add a comment, sign in
-